Voyager Therapeutics, Inc. (VYGR)
| Market Cap | 227.49M +16.1% |
| Revenue (ttm) | 36.49M -45.5% |
| Net Income | -116.64M |
| EPS | -1.98 |
| Shares Out | 60.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 837,207 |
| Open | 4.240 |
| Previous Close | 4.240 |
| Day's Range | 3.760 - 4.290 |
| 52-Week Range | 2.645 - 5.550 |
| Beta | 1.26 |
| Analysts | Strong Buy |
| Price Target | 16.50 (+338.25%) |
| Earnings Date | May 7, 2026 |
About VYGR
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small mo... [Read more]
Financial Performance
In 2025, Voyager Therapeutics's revenue was $40.37 million, a decrease of -49.53% compared to the previous year's $80.00 million. Losses were -$119.72 million, 84.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 338.25% from the latest price.
News
Voyager Therapeutics presents GLP for toxicology data for VY1706
Voyager Therapeutics (VYGR) presented three-month good laboratory practice, or GLP, toxicology data for VY1706, the Company’s investigational tau silencing gene therapy for Alzheimer’s disease, or AD,...
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mas...
Voyager Therapeutics reports Q1 EPS (47c), consensus (53c)
Reports Q1 revenue $2.59M, consensus $8.79M. “As the ‘Year of Tau’ for Alzheimer’s disease continues to unfold, Voyager looks forward to third-party data in mid-2026 that have the potential to…
Voyager Reports First Quarter 2026 Financial and Operating Results
- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended ...
Voyager Therapeutics management to meet with Oppenheimer
Meeting to be held on April 28 hosted by Oppenheimer.
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease
- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs -
Voyager Therapeutics management to meet with Oppenheimer
Meeting to be held on April 13 hosted by Oppenheimer.
Voyager Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
2026 is positioned as a pivotal year with major tau-targeted programs advancing, including gene therapy and antibody assets, and the first clinical use of BBB-penetrant capsids. Key data readouts and expanded partnerships are expected to drive progress in neurodegenerative disease innovation.
Voyager Therapeutics reports Q4 EPS (46c), consensus (51c)
Reports Q4 revenue $15.34M, consensus $10.49M. “Building on our pipeline progress in 2025, Voyager expects 2026 to be a pivotal year defined by three pillars of value creation: data on…
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies...
Voyager Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Three strategic pillars—tau-targeting, gene therapy, and NeuroShuttle—drive innovation, with two gene therapies entering the clinic and strong financial runway. Tau PET imaging is central to clinical development, and partnerships are key for advancing large-scale Alzheimer's trials.
Voyager to Present at Upcoming Investor Conferences
LEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced ...
Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Voyager Therapeutics (VYGR) to $25 from $30 and keeps a Buy rating on the shares. Voyager reported strong Q3 results, ending the…
Voyager Therapeutics Transcript: Stifel 2025 Healthcare Conference
The company is advancing a multimodal neurotherapeutics pipeline, with a strong focus on Alzheimer's and Tau-targeted therapies, including gene therapy and antibody programs. Key assets are progressing toward clinical readouts, and strategic partnerships support expansion into additional neurodegenerative and rare disease indications.
Voyager Therapeutics files $400M mixed securities shelf
16:09 EST Voyager Therapeutics (VYGR) files $400M mixed securities shelf
Voyager Therapeutics price target lowered to $11 from $12 at Leerink
Leerink lowered the firm’s price target on Voyager Therapeutics (VYGR) to $11 from $12 and keeps an Outperform rating on the shares. Voyager Therapeutics reported Q3 results and provided pipeline…
Voyager Therapeutics reports Q3 EPS (47c), consensus (52c)
Reports Q3 revenue $13.365M, consensus $7.86M. “Voyager continues to seek out the optimal modalities for each neurotherapeutic target we pursue. During the third quarter, we shared initial preclinical...
Voyager Therapeutics expects cash to fund operations into 2028
Voyager is committed to maintaining a strong balance sheet that supports the advancement and growth of its platform and pipeline. Based on Voyager’s current operating plans, the company expects its…
Voyager Therapeutics, Transition Bio entered into drug discovery collab
Transition Bio and Voyager Therapeutics (VYGR) have entered into a drug discovery collaboration and license option agreement. The companies will collaborate to discover and develop novel, selective sm...
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomol...
Voyager Reports Third Quarter 2025 Financial and Operating Results
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery progr...
Voyager Therapeutics Transcript: Baird Global Healthcare Conference 2025
The session highlighted a multimodal neurotherapeutics strategy, with a focus on Alzheimer's and Tau-targeted programs, including a pathologic-specific antibody and gene therapy entering the clinic next year. NeuroShuttle and ALPL shuttles show promise, and strong partnerships plus a $262M cash runway support upcoming milestones.
Voyager Therapeutics Transcript: Citi's Biopharma Back to School Conference
The company is advancing a robust neurotherapeutics pipeline, with four clinical programs expected by 2026 and a focus on validated CNS targets. Its Neuro Shuttle platform, highlighted by ALPL receptor data, aims to optimize brain delivery for diverse modalities. Cash runway extends into 2028, supporting ongoing clinical and partnered programs.
Voyager Therapeutics price target lowered to $8 from $9 at Wedbush
Wedbush lowered the firm’s price target on Voyager Therapeutics (VYGR) to $8 from $9 and keeps an Outperform rating on the shares. The firm notes the quarterly update reported runway…
Voyager Therapeutics reports Q2 EPS (57c), consensus (52c)
Reports Q2 revenue $5.2M, consensus $9.5M. “We firmly believe Voyager’s science has the potential to drive transformative neurotherapeutics, and that the efficiencies we have created this year give us...